Summary

Current guidelines recommend non-nucleoside reverse transcriptase inhibitor (NNRTI)-based, boosted protease inhibitor (PI)-based, and integrase strand transfer inhibitor (INSTI)-based regimens for the treatment of HIV [http://aidsinfo.nih.gov/Guidelines/HTML/1/adult-and-adolescent-treatment-guidelines/0; Thompson MA et al. JAMA 2012]. This article discusss recent data from clinical trials comparing initial antiretroviral regimens and factors to be considered when starting antiretroviral therapy.